CONMED Corp — Director's Dealing 2021

Oct 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED Corp (CNMD)
CIK: 0000816956
Period of Report: 2021-10-04

Reporting Person: Garner Todd W (Executive Vice President & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-04	Common Stock	S	58	$129.327	Disposed	133	Direct
2021-10-04	Common Stock	S	81	$130.129	Disposed	52	Direct
2021-10-04	Common Stock	S	20	$131.625	Disposed	32	Direct
2021-10-04	Common Stock	S	32	$132.985	Disposed	0	Direct
2021-10-04	Common Stock	M	8400	$50.61	Acquired	8400	Direct
2021-10-04	Common Stock	S	3117	$129.378	Disposed	5283	Direct
2021-10-04	Common Stock	S	3083	$130.048	Disposed	2200	Direct
2021-10-04	Common Stock	S	800	$131.492	Disposed	1400	Direct
2021-10-04	Common Stock	S	900	$132.651	Disposed	500	Direct
2021-10-04	Common Stock	S	500	$133.446	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-04	Options To Purchase Common Stock	$50.61	M	8400	Disposed	2028-01-02	Common Stock (8400)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.75 to $129.73. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.75 to $130.72. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.34 to $131.91. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.79 to $133.15. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F5: All of the exercises and sales submitted on this form were subject to a written 10b5-1 plan.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.72 to $129.69. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.72 to $130.60. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.92 to $131.91. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.11 to $133.10. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.13 to $133.99. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F11: Each Stock Option represents a contingent right to receive one share of common stock, par value $0.001, per share of Conmed Corporation (the "Company") and was granted outside of the Company's existing equity plan as "employment inducement grants" under NASDAQ Listing Rule 5635(c)(4) and vest in equal amounts (20%) over a five year period on the January 2 anniversary date of the award, as further described in the Current Report filed with the SEC by the Company on January 2, 2018.